Biosensors have been flourishing in the field of drug discovery with pronounced
developments in the past few years. They facilitate the screening and discovery of innovative …

The ubiquitin E3 ligase substrate adapter cereblon (CRBN) is a target of thalidomide and
lenalidomide, therapeutic agents used in the treatment of haematopoietic malignancies …

The drugs lenalidomide and pomalidomide bind to the protein cereblon, directing the CRL4–
CRBN E3 ligase toward the transcription factors Ikaros and Aiolos to cause their …

Cereblon (CRBN) is a ubiquitously expressed E3 ligase substrate receptor and a key player
in pharmaceutical targeted protein degradation. Despite substantial insight gained into its …

Oxidative stress due to abnormal accumulation of reactive oxygen species (ROS) is an
initiator of a large number of human diseases, and thus, the elimination and prevention of …

A modular chemistry toolbox was developed for cereblon-directed PROTACs. A variety of
linkers was attached to a CRBN ligand via the 4-amino position of pomalidomide. We used …

In targeted protein degradation, immunomodulatory drugs (IMiDs) or cereblon (CRBN) E3
ligase modulatory drugs (CELMoDs) recruit neo-substrate proteins to the E3 ubiquitin ligase …

The protein cereblon serves as a substrate receptor of a ubiquitin ligase complex that can be
tuned toward different target proteins by cereblon-binding agents. This approach to targeted …

Targeted protein degradation via cereblon (CRBN), a substrate receptor of an E3 ubiquitin
ligase complex, is an increasingly important strategy in various clinical settings, in which the …

Immunomodulatory imide drugs (IMiDs) such as thalidomide, pomalidomide, and
lenalidomide are the most common cereblon (CRBN) recruiters in proteolysis-targeting …